丙酮酸乙酯对高动力性肺高压的治疗作用

doi:10.6040/j.issn.1671-7554.0.2015.107

摘要/Abstract

摘要： 目的探讨丙酮酸乙酯对高动力性肺高压的治疗作用。方法以颈总动脉-颈内静脉套管法建立高动力性肺高压的大鼠模型,实验分为假手术组、分流组、治疗组和对照组,每组10只。治疗组腹腔注射EP 30 d[50 mg/(kg·d)],对照组腹腔注射等量生理盐水。治疗后测定各组肺动脉压力,计算右心室肥大指数(RVHI),肺组织切片HE染色计算直径厚度百分比(WT%)和管壁面积百分比(WA%),ELISA法测定血清TNF-α和IL-6水平,Western blotting法检测肺组织NF-κB p65的表达。结果治疗组较对照组肺动脉收缩压和右心室肥大指数明显降低,WT%和WA%明显下降。治疗组较对照组血清中IL-6和TNF-α明显降低,NF-κB p65表达明显降低,差异均有统计学意义(P<0.05)。结论丙酮酸乙酯可降低高动力性肺动脉高压大鼠内NF-κB p65的表达,减少细胞因子(TNF-α、IL-6等)的合成释放,减轻炎症反应,抑制肺动脉血管重构从而达到对高动力性肺动脉高压的治疗作用。

关键词: 核因子-κB p65, 肿瘤坏死因子-α, 白细胞介素-6, 丙酮酸乙酯, 肺动脉高压

Abstract: Objective To evaluate the effects of ethyl pyruvate (EP) on hyperkinetic pulmonary arterial hypertension (PAH). Methods Rat hyperkinetic PAH models were established by shunting common carotid artery and internal jugular vein. After that, 30 rat models were randomly divided into 3 groups, with 10 rats in each group: EP treatment group, control group, and shunt group. Another 10 rats were enrolled in the sham-operation group as negative controls. Rats in the EP treatment group were given intraperitoneal injection of EP [50 mg/(kg·d)] for 30 days, and rats in the control group were injected with the same volume of normal saline. The systolic pulmonary arterial pressure (SPAP) was measured after that and then the right ventricular hypertrophy index (RVHI) was calculated after the heart was removed. The percentage of diameter thickness (WT%) and wall area (WA%) were calculated in lung tissues stained with HE. The levels of TNF-α and IL-6 in the serum were measured with ELISA and expression of NF-κB p65 in lung tissues was detected with Western blotting. Results Compared with shunt group, EP treatment group had significantly decreased SPAP, RVHI, WT%, WA%, the levels of TNF-α and IL-6 in serum, and expression of NF-κB p65 in lung tissues. Conclusion EP could ameliorate PAH and inhibit the remodeling of pulmonary blood vessels in hyperkinetic PAH rats by reducing the expression of NF-κB p65, synthesis and release of cytokines (TNF-α, IL- 6, etc.) and alleviate inflammation reaction.

Key words: Nuclear factor-κB p65, Ethyl pyruvate, Pulmonary arterial hypertension, Tumor necrosis factor alpha, Interleukin-6

中图分类号:

R574

唐蒙蒙, 金女娃, 刘传振, 刘凯, 曹广庆, 王鹤, 庞昕焱, 吴树明. 丙酮酸乙酯对高动力性肺高压的治疗作用[J]. 山东大学学报（医学版）, 2015, 53(5): 75-80.

TANG Mengmeng, JIN Nüwa, LIU Chuanzhen, LIU Kai, CAO Guangqing, WANG He, PANG Xinyan, WU Shuming. Effects of ethyl pyruvate in the treatment of hyperkinetic pulmonary hypertension[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(5): 75-80.

参考文献

[1] 李强强, 顾虹, 罗毅. 先天性心脏病合并肺动脉高压的药物治疗进展[J]. 心肺血管病杂志, 2009, (3): 212-214. LI Qiangqiang, GU Hong, LUO Yi. Treatment progress of drugs for pulmonary hypertension with congenital heart disease[J]. Journal of Cardio Vascular Disease, 2009, (3): 212-214.
[2] 黄智伟, 吴炳祥. 肺动脉高压联合药物治疗的研究进展[J]. 心血管病学进展, 2009, 30(1): 109-111. HUANG Zhiwei, WU Bingxiang. The progress of pulmonary hypertension with combinated medication treatment[J]. Adv Cardiovasc Dis, 2009, 30(1): 109-111.
[3] Steinhorn RH, Fineman JR. The pathophysiology of pulmonary hypertension in congenital heart disease[J]. Artif Organs, 1999, 23(11): 970-974.
[4] 杨恒, 吕和平, 周蒙滔, 等. 丙酮酸乙酯对大鼠重症急性胰腺炎肾损伤的保护作用[J]. 肝胆胰外科杂志, 2011, 23(2): 89-91. YANG Heng, LV Heping, ZHOU Mengtao, et al. The protection of EP for kidney injury with severe acute pancreatitis in rats[J]. Journal of Hepatopancreatobiliary Surgery, 2011, 23(2): 89-91.
[5] Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion[J]. Intensive Care Med, 2003, 29(11): 2050-2058.
[6] Liu C, Yan Z, Fang C, et al. Establishment and comparison of two reliable hyperkinetic pulmonary hypertension models in rabbits[J]. J Thorac Cardiovasc Surg, 2014, 148(5): 2353-2359.
[7] Liu K, Liu R, Cao G, et al. Adipose-derived stromal cell autologous transplantation ameliorates pulmonary arterial hypertension induced by shunt flow in rat models[J]. Stem Cells Dev, 2010, 20(6): 1001-1010.
[8] 刘凯. 脂肪间充质干细胞移植治疗高动力性肺动脉高压的实验研究[D]. 山东大学, 2011.
[9] Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry[J]. Int J Cardiol, 2007, 120(2): 198-204.
[10] D'alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J]. Ann Intern Med, 1991, 115(5): 343-349.
[11] Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death[J]. Eur Heart J, 1998, 19(12): 1845-1855.
[12] Luan ZG, Zhang J, Yin XH, et al. Ethyl pyruvate significantly inhibits tumour necrosis factor-α, interleukin-1β and high mobility group box 1 releasing and attenuates sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury[J]. Clin Exp Immunol, 2013, 172(3): 417-426.
[13] Wang Y, Jing L, Zhao XM, et al. Protective effects of hydrogen-rich saline on monocrotaline-induced pulmonary hypertension in a rat model[J]. Respir Res, 2011, 12(6): 26.
[14] 刘传振. hHIF-1α基因转染内皮祖细胞移植治疗高动力性肺动脉高压的实验研究[D]. 山东大学, 2014. LIU Chuanzhen. Combined human HIF-la and homogeneous endothelial progenitor cells therapy attenuates hyperkinetic pulmonary arterial hypertension in rabbits[D]. Shandong University, 2014.
[15] Taylor MD, Grand TJ, Cohen JE, et al. Ethyl pyruvate enhances ATP levels, reduces oxidative stress and preserves cardiac function in a rat model of off-pump coronary bypass[J]. Heart Lung Circ, 2005, 14(1): 25-31.
[16] Yang R, Gallo DJ, Baust JJ, et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock[J]. Am J Physiol Gastrointest Liver Physiol, 2002, 283(1): 212-221.
[17] Fink MP. Ethyl pyruvate[J]. Curr Opin Anaesthesiol, 2008, 21(2): 160-167.
[18] Van Zoelen MA, Bakhtiari K, Dessing MC, et al. Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells[J]. Thromb Haemost, 2006, 96(6): 789.
[19] Hessel MH, Steendijk P, Den Adel B, et al. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat[J]. Am J Physiol Heart Circ Physiol, 2006, 291(5): 2424-2430.
[20] Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension[J]. N Engl J Med, 2004, 351(14): 1425-1436.
[21] Martin KB, Klinger JR, Rounds SI. Pulmonary arterial hypertension: new insights and new hope[J]. Respirology, 2006, 11(1): 6-17.
[22] Price LC, Wort SJ, Dorfmuller P, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1): 210-221.
[23] Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients[J]. Eur Respir J, 1998, 11(3): 554-559.
[24] Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3–microRNA cluster 17/92 pathway[J]. Circ Res, 2009, 104(10): 1184-1191.
[25] Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension[J]. Circ Res, 2009, 104(2): 236-244.
[26] Marsh CB, Wewers MD. The pathogenesis of sepsis: factors that modulate the response to gram-negative bacterial infection[J]. Clin Chest Med, 1996, 17(2): 183-197.
[27] Dunican AL, Leuenroth SJ, Grutkoski P, et al. TNF alpha-induced suppression of PMN apoptosis is mediated through interleukin-8 production[J]. Shock, 2000, 14(3): 284-289.
[28] Blackwell TS, Christman JW. The role of nuclear factor-κ B in cytokine gene regulation[J]. Am J Respir Cell Mol Biol, 1997, 17(1): 3-9.

相关文章 15

[1]	张栾,陈欧,栾云,朱晓波,陈元,王一彪. Gemigliptin对野百合碱诱导的肺动脉高压大鼠治疗作用及炎症因子的影响[J]. 山东大学学报（医学版）, 2017, 55(5): 19-22.
[2]	许天一,吴萍,王爱玲,陈丽萍. 米力农雾化治疗小儿重症肺炎合并心力衰竭的疗效[J]. 山东大学学报（医学版）, 2016, 54(7): 88-90.
[3]	李红志,刘静,宋岩,迟令懿,刘玉光. 利拉鲁肽对脊髓损伤修复作用的探讨[J]. 山东大学学报（医学版）, 2016, 54(4): 1-5.
[4]	潘艳艳,孙永超,赵翠芬,孔清玉. 波生坦治疗婴儿先心病合并肺动脉高压的临床观察[J]. 山东大学学报（医学版）, 2016, 54(2): 53-56.
[5]	刘慧敏, 刘邓, 李晓宇, 邹淑奉, 姜黎民, 李玉环. 半边莲生物碱对肺动脉高压大鼠ET-1信号通路的影响[J]. 山东大学学报（医学版）, 2015, 53(8): 1-4.
[6]	王静, 高桂新, 万云焱, 刘庆华, 姚周虹, 林殿杰. 益气活血养阴解毒方对放射性肺损伤中TGF-β1、TNF-α表达的影响[J]. 山东大学学报（医学版）, 2015, 53(7): 13-18.
[7]	蔺晨, 郭芳, 季维娜, 于文成. 社区获得性肺炎患者的外周血TNF-α、sTREM-1、α1-APG水平[J]. 山东大学学报（医学版）, 2015, 53(2): 61-64.
[8]	张庆伟1，王春亭2，王启志2，张琳2，王鹏2，孟玫2. 丙酮酸乙酯对脓毒症大鼠小肠黏膜屏障的保护作用及其机制[J]. 山东大学学报（医学版）, 2014, 52(5): 30-34.
[9]	王亚云1, 王一彪1, 张雪1, 林梅1, 苏宏1，马宇1，朱晓波1, 陈欧2. PS-341对肺动脉高压大鼠Nrf2/NF-κB表达的影响及作用机制[J]. 山东大学学报（医学版）, 2014, 52(2): 6-11.
[10]	孙越,刘香岚,王群,郭春,石永玉,张利宁. 人TIPE家族新成员TIPE3特异性抗体的鉴定及应用[J]. 山东大学学报（医学版）, 2014, 52(1): 5-9.
[11]	孟庆红1，赵翠芬1，孔清玉1，李福海1，李栋2，夏伟1. 尾加压素Ⅱ对大鼠肺动脉平滑肌细胞胶原合成的影响[J]. 山东大学学报(医学版), 2013, 51(5): 15-19.
[12]	韩晓娟1，马学强2，杜怡峰1. 海风藤提取物对Aβ寡聚体激活的小胶质细胞释放炎性因子的抑制作用[J]. 山东大学学报(医学版), 2013, 51(5): 6-10.
[13]	薛明华1，张琴2，侯代伦1，徐庆国2，隋树建3. 组织多普勒成像对肺动脉高压患者右心功能的评价[J]. 山东大学学报(医学版), 2013, 51(4): 37-41.
[14]	吴文振1, 郝恩魁1,程义伟1，解崔环2,孟彦3,苏国海1. 不同急性肺动脉高压模型的建立及其血流动力学转归的实验研究[J]. 山东大学学报(医学版), 2012, 50(3): 34-39.
[15]	王月恒1，邢毅2，王玖玲1，代军3，李淑玲1. 多囊卵巢综合征患者血清内脂素及TNF-α的水平变化及其意义[J]. 山东大学学报(医学版), 2012, 50(2): 94-.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed